SCHEMBL12416633

SCHEMBL12416633

CCCCCCCCCc1ccc(/N=C/c2ccc(/C=N/c3ccc(CCCCCCCCC)cc3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.62
CYP2D6 P10635 2/20 0.62
CYP2C9 P11712 2/20 0.62
ESR1 P03372 2/20 0.50
ADRA2A P08913 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
TACR2 P21452 2/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
LMNA P02545 1/20 0.50
SHBG P04278 1/20 0.50
HSPD1 P10809 1/20 0.50
ADRB3 P13945 1/20 0.50
HTR2C P28335 1/20 0.50
HSPE1 P61604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3623036 1.00 CYP3A4 (0.62) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL10764013 1.00 CYP3A4 (0.62) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL12416611 0.97 CYP3A4 (0.58) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL10346503 0.97 CYP3A4 (0.58) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL1878786 0.95 CYP3A4 (0.57) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL3620867 0.93 CYP3A4 (0.60) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL11524101 0.93 CYP3A4 (0.60) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL6635785 0.93 CYP3A4 (0.60) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL7599363 0.92 CYP3A4 (0.55) CYP3A4CYP2D6CYP2C9ESR1ADRA2A
SCHEMBL8756807 0.92 ALDH1A1 (0.65) CYP3A4CYP2D6CYP2C9ESR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-07-14 US disclosed
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS BID, BAD, MCL1 CYP3A4 1829/4885CYP2D6 3437/4885CYP2C9 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.